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Abstract
Standard implantable cardioverter-defibrillator with transvenous leads systems have proven to
be effective in terminating ventricular tachyarrhythmias in most patients (more then 90%)
with sufficient safety margin, i.e. difference between maximal output energy of the ICD and
defibrillation threshold. However in some clinical situation it is not possible, energy require-
ment is higher than normal, it is called high defibrillation threshold. We report clinical data of
3 patients with high defibrillation threshold among 415 ICD’s implanted in our institution
(cases of ischaemic cardiomyopathy, dilated cardiomyopathy and hypertrophic cardiomyopathy
are presented). We summarize our experience, therapeutic options and literature review inves-
tigating factors which influence defibrillation threshold: related to underlying cardiac disease,
therapy (drugs interactions) and ICD system( lead and pulse generator type). (Folia Cardiol.
2006; 13: 396–403)
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Introduction
The technological development of an implan-
table cardioverter-defibrillator (ICD) in the last
decade has made the transvenous implantation of
the device a fairly simple surgical procedure. ICD
miniaturisation, the possibility of subcutaneous
implantation, technically similar to that of cardiac
pacemaker, together with low intraoperative mor-
tality (according to some sources < 0.5%) [1] on
the one hand, and a significant number of trials pro-
ving the efficiency of this method of therapy in
primary and secondary prevention on the other [2, 3]
have caused a rapid increase in the number of im-
plantations performed. Nonetheless this therapeu-
tic method has its limitations like any other. The
number of complications is increasing, both surgi-
cal and psychological, which are more difficult to
evaluate and are often underesteemated [4, 5]. It
seems that the greatest problems are still ahead of
us since this branch of electrotherapy is still young
and we do not have enough experience or long-term
observations, for example in removing damaged le-
ads or long-term consequences of implanting ICDs
in children. Among many problems coming along
with this method of treatment a high defibrillation
threshold is one of the most difficult ones. It either
renders the implantation impossible in accord with
good clinical practice or leaves too narrow
a safety margin after the procedure. In the latter
case a procedure has sometimes to be repeated, it
usually takes more time, is technically more com-
plicated than standard implantation and it does not
always end successfully. This article addresses the
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very problem, as seen in our own observations. The
definition of high defibrillation threshold has to be
recalled here. Defibrillation threshold (DFT) is the
simplest method of evaluating the efficacy of defi-
brillation impulse, defined as the lowest energy
output that terminates arrhythmia. Historically it
was stated that the difference between a given type
ICD’s maximum energy shock and DFT should not
be less than 10 J. This value dates back to the pe-
riod of developing the procedure in the 1990s. when
epicardial leads were used. The most recent stu-
dies on endocardial leads recommend the safety
margin of 1.9 DFT that guarantees a 95% efficien-
cy probability [6].
Besides the above mentioned need to leave
sufficient energy surplus in respect to maximum
energy output of a given defibrillator the DFT va-
lue influences longevity of the battery. Low DFT
values also eliminate the need to use additional le-
ads during the ICD implantation which of course
simplifies the procedure.
There are many factors influencing the defibril-
lation threshold. They can be divided with respect
to the patient (underlying disease), treatment (the
effect of the drugs) and the ICD system applied (the
lead and the impulses’ generator).
This article is a compilation of the experien-
ces gathered in our centre together with the review
of literature concerning the management of patients
with high defibrillation threshold.
Methods
In the II Department of Coronary Artery Dise-
ase, Institute of Cardiology in Warsaw, 415 cardio-
verter-defibrillators were implanted.
In our centre the DFT is determined intraope-
ratively, by an orientational method, testing the
DFT range from 10 J upward, so as to achieve suc-
cessful defibrillation, leaving the surplus margin of
10 J in respect to the device’s maximum energy
output. Practically we routinely test 3 energy valu-
es: 10, 15 and 20 J.
Only when DFT ranges between 20–30 J we
evaluate it very precisely. We believe that precise
evaluation of DFT in most patients is not useful
from the clinical point of view, it prolongs the pro-
cedure, requires multiple defibrillations (DF) and
needlessly uses up the device’s battery.
Using the technique described above, in 3 pa-
tients (0.72% of analysed group), we were not able
to achieve the determined safety margin during the
first procedure. We discuss these patients in the
chronological order.
Patient 1
A 71-year old man with post-infarction cardio-
myopathy was referred to our Department from
a county hospital where he was admitted due to ven-
tricular tachycardia with hypotension 90/50 mm Hg.
These symptoms were well tolerated by the patient.
Since pharmacotherapy was not effective, tachycar-
dia was terminated by 100 J electric cardioversion,
standard doses of amiodarone were administered
and the patient was transferred into our Department
for the ICD implantation. In the course of routine
diagnostic procedures a post-infarction heart failu-
re was diagnosed. Echocardiography and ventricu-
lography findings demonstrated large dyskinetic
aneurysm of the anterior heart wall, left ventricu-
lar ejection fraction (EF) about 20% and left ven-
tricular end-diastolic diameter (LVEDD) 7.2 cm.
Due to coronarography results the patient did not
qualify for revascularisation treatment (left anterior
descending artery (LAD) leading to the infarct zone
was totally occluded). The indications for ICD im-
plantation were determined. Intraoperatively, with
the lead typically placed (SPS 75UP/BP, Biotronik)
in the right ventricle’s apex, the maximum output
energy of the implanted ICD (Phylax 06, Biotronik)
=30 J did not terminate ventricular fibrillation (VF).
The lead was placed in different positions several
times, even with the unorthodox placement on the
interventricular septum. The successful intracar-
diac defibrillation was not achieved though. Natu-
rally all possible programmable parameters modi-
fications (impulse’s shape and leads’ polarity) were
tried as well. In that case, after consulting with the
manufacturer (no available subcutaneous net type
lead able to lower DFT) an additional lead SVC type
was implanted into superior vena cava. Unfortuna-
tely it did not help to achieve DFT < 30 J. Nume-
rous unsuccessful internal defibrillations (12 tries
overall) and successful termination of ventricular
fibrillation only after an external defibrillation with
maximum energy of 360 J delivered twice made the
team drop the implantation procedure.
After the failed procedure it was stated that
there are indications for buying a higher energy
device, which at that time (1997) required a con-
cession from the Ministry of Health. The patient had
no symptoms, had no recorded clinically significant
arrhythmias in repeated Holter ECG, serum ami-
darone level was in therapeutic range. Such being
the case the patient was discharged but remained
under Clinic’s ambulatory surveillance (regular con-
trols were performed every 2 months, including
Holter ECG). Eight months after the hospitalisation
the patient suddenly died at home.
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Patient 2
A 44-year old man with post-inflammatory car-
diomyopathy, after sudden cardiac arrest caused by
VF, successfully resuscitated by the family and la-
ter on by a medical emergency team. He was ad-
mitted into the Department for an ICD implanta-
tion as “a bridge therapy” while waiting for a plan-
ned heart transplant. He was diagnosed with
congestive heart failure NYHA III/IV, EF was abo-
ut 10%, LVEDD 9.1 cm (echocardiography’s pictu-
re is presented on Fig. 1). Intraoperatively with the
lead typically placed (KAINOX-SL 75/15 with two
defibrillating coils) in the right ventricle’s apex ma-
ximum energy output of implanted ICD (Mycrophy-
lax plus, Biotronik) = 30 J was not sufficient to ter-
minate VF. The lead was replaced several times,
with different positions being checked out. A suc-
cessful defibrillation was not achieved with satis-
factory DFT after modifying and checking out all
possible programmable parameters (impulse’s sha-
pe and lead’s polarity). Defibrillator was left in place
since the maximum energy output was efficient at
first try, although we were not able to reproduce this
effect for the second time. Another attempt was un-
dertaken 5 days after the first surgical procedure in
the presence of manufacturer’s representative who
was a high DFT specialist. A successful internal DF
was not achieved. Because of that the patient was
placed on emergency Poltransplant’s list, after con-
sulting the case with the cooperating transplantolo-
gy centre. He awaited the operation in Intensive
Cardiac Care Unit for two months due to a rare blo-
od type. The heart transplant with the ICD removal
was uncomplicated. The patient stays asymptoma-
tic in the Outpatients’ Transplantology department.
Patient 3
A 21-year old woman with hypertrophic cardio-
myopathy diagnosed a few years before was refer-
red into the Department for prophylactic implanta-
tion of an ICD, due to a high risk of sudden cardiac
arrest (large heart hypertrophy, a significant blood
pressure drop and signs of ischaemia in ECG du-
ring the ECG exercise test). She had had a cardiac
pacemaker AAI implanted previously due to a si-
nus node’s automatism insufficiency while treated
with a beta-blocker.
Echocardiography performed before the ope-
ration (Fig. 2) demonstrated a monstrous heart’s
muscle hypertrophy (interventricular septum width
= 4.5 cm, left ventricle free wall width = 5.0 cm)
and a hairline narrowing of both ventricles’ lumen.
Intraoperatively using the defibrillating lead with
two coils typically placed in the right ventricle’s
apex and a properly working pacing lead in the ri-
ght atrium’s aurix, maximum energy output of the
implanted ICD (Photon DR) = 30 J did not termi-
nate VF. The lead was replaced several times but
even after changing the lead into a screw-type
(TVL-ADX 1559, St. Jude Medical), repeating the
placing procedure complete with “on the interven-
tricular septum” position, a successful internal de-
fibrillation was not achieved. All possible modifica-
tions of programmable parameters were of course
checked out (impulse’s shape and lead’s polarity),
(the placing of the lead on this stage of the proce-
dure is shown on Fig. 3).The procedure was then
ended and a re-operation with higher energy devi-
ce implantation was planned. After asking for the
delivery of the highest energy ICD available on the
market = 36 J and a subcutaneous lead able to
Figure 1. Echocardiogram of dilated cardiomyopathy
demonstrating an enlarged left ventricle.
Figure 2. Echocardiogram of hypertrophic cardiomyo-
pathy demonstrating hypertrophy of the interventricu-
lar septum and left ventricle.
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decrease DFT by Medtronic, the date of the second
surgical procedure was set. The second procedure
took place 3 weeks after the first, in the presence
of manufacturer’s representative, a high DFT spe-
cialist. It started with trying to optimise the im-
pulse’s width according to a recommendation table
sent with the device ATLAS DR (ICD alternative
Defibrillation Bi-Phasic Waveform Pulse Width Re-
commendations). The efforts undertaken did not
bring about the awaited DFT lowering. In this case
the patient was re-operated, the lead was replaced
into the right ventricle’s apex and an additional lead
was placed in left subclavian vein (TLV SV02 Ven-
tritex, St. Jude Medical), so as to allow the defibril-
lation impulse to encompass the whole hypertro-
phied left ventricle. DFT was gauged with the leads
so placed (Fig. 4) and a borderline value of 22.5 J
was reached. Anticipating the progression of the
disease (continued hypertrophy) an ATLAS DR
device was implanted (it was the first procedure of
this kind in Poland). Its maximum energy output
36 J provided a satisfactory safety margin. Post-ope-
rative period was uncomplicated. The device test
5 days after the operation was satisfactory — elici-
ted ventricular fibrillation was successfully termi-
nated by ICD (25 J). Six months after the operation
the patient was asked to have another defibrillation
threshold assessment test but she refused. She re-
mains in ambulatory care and for 1.5 years she has
had no ICD interventions.
In the cases presented the operation time and
the X-ray radiation time were: 1) 188/20 min,
2) 120/6 min, 3) 210/6 min respectively and 150/12 min
during the re-operation.
Discussion
Chronologically presented clinical cases of va-
rious forms of cardiomyopathies show our centre’s
evolving views and experiences with respect to high
DFT treatment. The first, tragically ended one,
happened in the “pioneer” period in developing the
method in our country. Undoubtedly amiodarone tre-
atment, which does not prevent ventricular fibrilla-
tion, must have influenced DFT. Based on the obse-
rvations published afterwards, we know now that the
continuous amiodarone therapy increases the requ-
ired defibrillation energy by 62% (DFT before the
therapy 9.9 ± 4.6 J vs. 13.7 ± 5.6 J after reaching
the therapeutic doses of the drug p = 0.004) [7].
The effect disappears 3 months after the disconti-
nuation of the therapy. Some researchers postula-
te in case of treatment with III class antiarrhythmic
agents, changing the length of DF impulse’s second
phase — shortening P2 from 5 to 2 ms [8].
It is known nowadays which of the anti-arrhy-
thmic drugs can modify defibrillation threshold al-
though the available data is a little vague. Different
methodology and various clinical profile of the pa-
tients can yield opposing results. It is obvious when
compared with statistics that 50–70% of patients
with implanted ICD are treated with anti-arrhyth-
mic drugs that each case requires an individualised
assessment [9].
Among the DFT increasing drugs, apart from
the already mentioned amiodarone there are: ve-
rapamil, class IB drugs (lidocaine, mexiletine) and
class IC drugs (eg. propafenone). The list of drugs
Figure 3. Chest radiograph demonstrating position of
the impulse generator (Photon DR) and leads in cham-
bers of right heart.
Figure 4. Chest radiograph demonstrating position of
the impulse generator (Atlas DR) and leads in cham-
bers of right heart and SVC electrode (arrows) in supe-
rior vena cava, left brachio-cephalic vein and left sub-
clavian vein.
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decreasing DFT is much shorter: class III drugs
with the exclusion of amiodarone (“pure class III
effect”). In clinical practice in means sotalol only,
since other drugs have not been investigated in that
respect [10]. Based on the above mentioned facts
some researchers recommend checking DFT
3 weeks and 3 months after amidarone therapy has
been initiated, especially since there can be interac-
tions between ICD and anti-arrhythmic drugs other
than DFT changes (such as changing arrhythmia
cycle, pacing energy threshold or ATP efficacy) [9].
Apart from drugs’ effects described above, the-
re are other factors increasing DFT such as: pri-
mary disease progression, concomitant diseases,
hyperkalemia, hypoxia, ischaemia, pericardial or
pleural effusion, leads left in the heart or in the
vessels and prolonged ICD implantation procedure
with repeated defibrillations [10].
In clinical practice frequently chronic renal fa-
ilure is a disease influencing DFT. In the course of
the disease higher median values of DFT were ob-
served: 15 J when creatinine level is > 1.5 mg%
and 12.35 J when < 1.5 mg% [11].
The remaining safety margin is a crucial issue
in the case of high DFT value. There are reports
arguing that a threshold lower than historical 10 J
is acceptable, although in such patients defibrilla-
tion efficacy tends to decrease after a year’s obse-
rvation. In one report 445 patients were divided into
two groups: 1) 2–6 J safety margin with regard to
DFT and 2) 6–12 J safety margin. Defibrillation ef-
ficacy was compared in these groups in a pre-
-discharge test and after a year. In the two points of
time and in the group 2 as compared to 1 defibrilla-
tion efficacy was: 100% vs. 99% and 99.6% vs.
96.4% respectively, p = 0.01 [12].
Because of this some researchers postulate not
only a pre-discharge test but a routine full test of
the implanted ICD in a sedated patient two months
after the implantation, to control DFT among other
parameters [13]. In this trial 227 patients with a pre-
discharge control test had another control test after
2 months. In 24 of them significant ICD abnormali-
ties requiring correction were found, among others
sensing disorders and lead displacement. Six of the
patients (5%) required re-operation and in 8% of the
patients DFT increase to > 25 J was detected. Some
believe that DFT has to be controlled at least once
a year, a fact that tends to be forgotten in the every-
day practice [14]. The experience gathered up to date
shows that 15% patients will have DFT increase
> 10 J and 3% will need a re-operation because of that.
Lead’s polarity is a well known programmable
parameter influencing DFT. The system in which
a lead implanted into right ventricle’s apex is an
anode (+) is known to have lower DFT value com-
pared to the one in which this lead is a katode.
There is a minority of patients (about 12%) in
which the situation described above is reversed [15].
The manoeuvre commonly referred to as polarity
reversal is therefore always worth trying since it
requires only a programmer and an assessment
of DFT in both situations [15].
The second case described presents a patient
in the last stages of post-inflammatory dilated car-
diomyopathy but the high defibrillation threshold
problem stems from the left ventricle dilatation,
regardless of etiology either inflammatory or more
often ischaemic. With left ventricular diastolic dia-
meter so increased (LVEDD = 9.1; Fig. 1) and the
whole heart enlargement, a lead typically placed in
the right ventricle’s apex and the device’s active can
might not be able between them to encompass the
whole of the left ventricle mass with the delivered
defibrillation impulse. A similar situation although
caused by a different mechanism (hypertrophy in-
stead of dilatation) occurred in the third case de-
scribed. In such instances using a lead with two coils
placed this way: distal in right ventricle, proximal
in superior vena cava, left brachio-cephalic vein or
left subclavian vein (Fig. 5) or adding a superior vena
Figure 5. Chest radiograph demonstrating position of
the two shocking coil lead: distal in the right ventricle
apex and proximal in left brachio-cephalic vein and left
subclavian vein.
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cava type lead (the so-called floating lead (Fig. 4),
lead marked with an arrow) to one-coid lead seems
to be advantageous.
Placing the second (proximal) defibrillating
spiral exactly in a way described above seems to
be of crucial importance. There are some clinical
trials proving that placing the lead in a lower part of
the right atrium not only does not decrease DFT but
tends to increase it, although not significantly [16].
As for the placement of the proximal lead in the
superior vena cava the reports differ as to its influ-
ence on DFT. Some have shown its positive effect
on lowering DFT [17, 18], others quite on the con-
trary [19]. There are reports of placing the additio-
nal lead in inferior vena cava, which according to
the authors lowers DFT by 38% [20]. There are no
randomised trials referring to additional lead place-
ment in subclavian vein or left brachio-cephalic vein,
though according to theoretical point of view such
placement should be the most advantageous.
Due to the dynamic development of re-syn-
chronizing therapy other unorthodox positions
of leads in the heart’s veins, designed to lower
DFT were described [21, 22]. The latter of the cal-
led reports showed DFT lowering by 45–50%.
The former’s conclusions were more cautious: such
a significant lowering of DFT was observed using
a biventricular system (with the additional lead in
anterior or posterior left coronary vein) as compa-
red to the standard right ventricle system but me-
dial DFT in both groups did not differ significantly
and further investigation is needed.
Although the typical placement of defibrillating
lead in the right ventricle’s apex and the device’s
active can in left subclavian region is sufficient to
obtain acceptable DFT values in the majority of pa-
tients (> 90%) [16, 23], some patients may require
additional endocardial leads (mentioned above) or
subcutaneous leads. The latter in the form of a sub-
cutaneous net are available on all ICD manufactu-
rers’ offer. They are placed in the subcutaneous tis-
sue or between the thoracic cage wall muscles in V
intercostal space, on level with a nipple. This kind
of solution makes the surgical procedure more
extensive and more time-consuming, which incre-
ases the risk of complications, among others inflam-
matory. Lead type 6996 SQ (Medtronic) seems to
be a promising solution in the cases of high DFT. It
has a small diameter, can be placed in the interco-
stal space after tunnelling, reaching as far as the
spine (the lead’s end), in the posterior thoracic cage
region. It is much easier to place it with surgical
technique, compared to “patch” type leads. The sys-
tem: a lead described above placed on thoracic
cage’s posterior wall, standard lead in the right ven-
tricle’s apex plus an impulse’s generator active can
guarantee optimum energy flow, encompassing the
whole heart. The system described above can be
modified by placing the additional lead in the supe-
rior vena cava.
The second patient’s history also calls to mind
a problem of protecting patients awaiting the heart
transplant or the patients with contraindications for
a standard operation (for example treated for an
infection) or patients refusing to undergo ICD im-
plantation, from sudden cardiac arrest. The results
of two trials: WEARIT and BIROAD investigating
the use of continuously worn external defibrillators
have unanimously shown the effectiveness of this
method in preventing sudden cardiac death [24, 25].
The devices of this kind currently manufactured can
deliver a maximum energy output of 285 J for the
monophasic impulse and 150 J for biphasic impul-
se. It seems that the latter function finds its use in
cases of high defibrillation threshold, obviously after
performing a provocation trial in each individual
case [25]. The devices of this kind find their use in
other clinical situations, such as: patients awaiting
for an ICD implantation, previously implanted ICD’s
lead or defibrillator damage, potentially reversible
cause of arrhythmia for a time needed for its remo-
val (patients with ischaemia waiting for revascula-
risation procedure, with drug intoxication, in early
post-operative period and so on). There is also
a growing number of patients with contraindications
to ICD implantation due to a poor health, concomi-
tant diseases or predicted short survival period after
the procedure.
Based on the available data it is believed, that pro-
viding large centres treating patients with a high risk
of sudden cardiac deth and heart transplant centres
with external defibrillators of this kind is justified.
The use of automated external defibrillators
(AED) becomes another solution to the problem of
protecting high risk SDC patients (including pa-
tients with high DFT). Recently published Europe-
an standards on this issue explicitly point out the
importance of these devices in treating ventricular
tachyarrhythmias [26]. Among indications to use
the device in patient’s house, protection of the high
risk patients is quoted, in whom “ICD implantation
is not indicated, is not possible or is not planned at
present”. The cost analysis of introducing the AED
programme presented in these standards evaluates
one year of life saved to be worth $ 16.060. Medi-
cal’s procedure costs presented like this and amo-
unting to less than $ 20.000 are considered very
reasonable in American standards.
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To sum up, the data about the factors influen-
cing defibrillation threshold in patients with trans-
venously implanted ICD, an individual assessment
of any given patient has to be made like in any other
clinical situation. There are very few reports try-
ing to define prognostic factors predicting the oc-
currence of high DFT [27], which might help in pre-
paring beforehand for such difficult procedure, for
example providing the hardware needed (such as
special types of leads and high energy impulse’s
generator). The prospective analysis of 102 patients
investigated in the report cited established that only
4 of 34 parameters (clinical, echocardiographic and
electrophysiologic) are of any importance. They are:
QRS width, intraventricular septum width, left ven-
tricle mass and mass index. The significance of the
left ventricular ejection fraction, LVEDD or conco-
mitant amidarone therapy were not confirmed [27].
All previous investigations addressing this problem
were conducted with monophasic, not biphasic im-
pulse treatment — the latter being now a standard
procedure (as in the investigation cited above)
— and epicardial instead of endocardial leads. They
confirmed male gender, amiodarone therapy [28] or
male gender and low left ventricular ejection frac-
tion [29] as significant prognostic factors. In inve-
stigations assessing endocardial systems high DFT
risk factors were: male gender, amiodarone thera-
py, cardiomegaly, left ventricle dilatation, congesti-
ve heart failure, measured body surface [30–34],
although in none of them left ventricular ejection frac-
tion was confirmed as being significant, paradoxically.
Nowadays a single lead with two coils and
a standard ICD are being most commonly used,
as this system has the lowest DFT values.
The last of the presented patients in the end
was given a higher energy class ICD compared to
the standard device. Apart from the described mo-
del (Atlas VR and DR, St. Jude Medical: 36/42 J
output energy/accumulated energy respectively)
there are comparable high energy devices by other
manufacturers, for example Ventak Prizm HE VR
and DR, Guidant: 35/41 J, Gem SR and DR, Med-
tronic: 35/39 J. These devices are of a size compa-
rable to the standard energy ICDs, unfortunately
their price is much higher. However, when a satis-
factory DFT cannot be achieved with an implanta-
tion of a standard device, using a high energy out-
put defibrillator is to be considered.
Although in the case described changing the
defibrillation impulse’s form (tilt 50% instead of
a standard 65% and changing I and II phase width
as recommended by the manufacturer (DFT Mana-
gement Kit, St. Jude Medical) did not bring about
the desired effect, optimising the programmable pa-
rameters of an ICD should be tried in each indivi-
dual case.
There are situations when satisfactory DFT
values cannot be achieved, even after exhausting
every possible set of endocardial system, coupled
with subcutaneous lead implantation. The chrono-
logically oldest method is to be considered then
— that is the implantation of a defibrillator with an
epicardial lead in a heart surgery centre, although
even this approach does not guarantee success.
Conclusions
1. In each patient with a high defibrillation thre-
shold all possible potentially reversible causes
should be considered.
2. Unorthodox endocardial system: an additional
lead and/or changing the lead’s position or re-
versing lead’s polarity may provide a solution
to the problem. These procedures lower DFT
in some of the patients (the so-called optimi-
sing the impulse’s vector).
3. Currently available programmer’s software al-
lows for non-invasive modification of numero-
us ICD’s parameters influencing DFT value,
such as defibrillating impulse shape and width
(the so-called optimising the impulse).
4. When all above mentioned methods of lowering
DFT fail, the use of subcutaneous leads, implan-
ting higher energy device or lastly implanting
an epicardial electrode are to be considered.
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